Glonghui, December 25 | According to a report published by Daimo for the third quarter, according to Shanghai Pharmaceutical's quarterly results for the third quarter, the company's profit forecast from 2023 to 2030 was lowered by about 4% to 8%, based on low sales in the manufacturing sector, and its target price was lowered from HK$19 to HK$18, maintaining the “increase in holdings” rating.
大行评级｜大摩：下调上海医药目标价至18港元 维持“增持”评级
Bank Ratings｜Daimo: Lowering the target price of Shanghai Pharmaceuticals to HK$18 to maintain “increased holdings” rating
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.